Datavault AI Inc. provides data monetization, credentialing, digital engagement and real-world asset tokenization technologies through a cloud-based platform spanning Acoustic Sciences and Data Sciences. Its recurring announcements describe AI-driven data experiences, asset valuation and monetization, Information Data Exchange® capabilities for Digital Twins and name, image and likeness licensing, and patented audio technologies including WiSA, ADIO and Sumerian.
Company news also covers registered equity offerings, use of proceeds for a quantum-ready GPU edge network, financial-results communications, and material agreements tied to tokenized assets and exchange technology. Updates often connect Datavault AI's common stock capital structure with product deployment, licensing, analytics, marketing automation and industry applications in sports and entertainment, education, fintech, healthcare, energy and other markets.
Datavault AI (NASDAQ:DVLT) expanded its WiSA wireless audio portfolio with 13 U.S. patent milestones recorded year-to-date in 2026.
The milestones comprise three issued patents and 10 applications receiving Notices of Allowance. The issued patents cover audio source localization, concealment of audio interruptions and multi-speaker speech processing. The allowed applications address wireless transmission, synchronization, interoperability and device pairing, among other areas. Additional patent issuance remains subject to completion of applicable requirements. Datavault AI plans to pursue potential licensing, technology partnerships and standards-related opportunities; commercialization remains dependent on patent rights, market adoption and negotiations.
Datavault AI (DVLT) signed a non-binding letter of intent to acquire a 19.9% equity interest in DataMEDS AI through an expanded technology license. The proposed stake would be on a fully diluted basis, accounting for potential share issuance. Datavault AI would retain its underlying intellectual property, while DataMEDS would bear commercialization costs.
The expanded license would be exclusive, subject to specified exceptions. Datavault AI could participate in potential royalties and designate one DataMEDS director after closing. The company considers a fourth-quarter 2026 closing realistic. Completion depends on due diligence and definitive agreements; neither party is obligated to complete the transaction without them. The patents and applications covered remain subject to confirmation in the definitive license schedule.
DataMEDS AI (MEDS) entered an amended non-binding letter of intent to license healthcare technologies and acquire intellectual property and control of Tollo Health. The October 19, 2026 agreement would expand its Datavault AI (DVLT) healthcare license, add an exclusive Data Health Partners license, and acquire QOLPOM intellectual property from EOS and Scilex (SCLX). The assets cover patient goal tracking, biometric medication-delivery verification and wearable-based monitoring of drug effects. DataMEDS would acquire Tollo Health control from HealthBridge Advisors.
The company expects closing in fourth-quarter 2026. A majority of DataMEDS shareholders approved draft definitive agreements, subject to satisfactory management due diligence. Execution remains pending, alongside a fairness opinion, an outstanding-liabilities threshold and Nasdaq requirements, including change-of-control review. Existing third-party licenses limit the proposed Datavault rights.
DataMeds AI (NASDAQ:MEDS) has regained compliance with Nasdaq’s minimum stockholders’ equity requirement, following a notification dated October 19, 2026. The requirement is $2.5 million, and the company’s October 13 filing confirmed equity exceeded that threshold. An October 16 filing supplied additional details on the events behind the increase.
Nasdaq had notified DataMeds of delisting proceedings in April over bid-price and equity deficiencies. Bid-price compliance was restored in June. The company may face delisting if it fails to demonstrate compliance when filing its next periodic report.
DataMeds AI (NASDAQ:MEDS) outlined subsidiary Corexa Health’s peptide business plans following the FDA’s proposed interim policy for compounding certain peptides. The proposal follows an advisory committee recommendation to loosen restrictions on six peptides; it is not yet effective.
Corexa Pharmacy plans to fill prescriptions for eligible peptides once the policy takes effect. It has begun reviewing drug-substance suppliers and intends to formalize contracts in the coming weeks. Corexa Distribution, licensed in all 50 states, plans to work with prospective manufacturers and its network of 6,500+ independent pharmacies to expand access.
DataMeds expects the peptide market to be predominantly cash pay initially, potentially reducing Corexa Pharmacy’s exposure to insurance reimbursement challenges. Its Tech & Hub division routes prescriptions to Corexa Pharmacy or a patient’s chosen local pharmacy.
Datavault AI (DVLT) received a notice of allowance for its Data Futures Platform patent application from the U.S. Patent and Trademark Office. Application No. 17/441,847 describes asset valuation, token creation and digital-marketplace transactions, including blockchain-based verification records.
The company believes the technology may be relevant to tokenized securities infrastructure following the SEC's September 17, 2026 temporary, conditional exemption for qualifying venues trading certain tokenized National Market System stocks. The exemption does not constitute SEC endorsement of Datavault AI or its intellectual property. Datavault AI intends to assess potential commercial partnerships and alignment with emerging market requirements.
DataMeds AI (MEDS) signed an exclusive agreement with REBOOT Health AI for U.S. direct-to-consumer rights to its care management platform. The agreement covers licensing, revenue sharing and marketing for a platform supporting patients taking GLP-1 weight management medications. DataMeds will share revenue from subscriptions related to the platform.
DataMeds plans to integrate REBOOT's technology into its Health Lives Here mobile app, conduct pilot programs and launch commercially. Planned weight care support modules will be offered through monthly subscriptions. REBOOT's patent family includes six patents and six pending applications. DataMeds expects the subscription services also to drive revenue from pharmacy dispensing, nutraceutical sales, diagnostic lab testing and physician services. The app is available on Android and iOS.
Datavault AI (Nasdaq: DVLT) appointed Jeffrey Tirman to its Board of Directors, effective October 12, 2026, following its acquisition of NYIAX.
NYIAX designated Tirman in connection with the recently completed acquisition; he previously served on NYIAX's board. Through his family office, Abri Capital, he holds 26 million DVLT shares. Tirman brings more than 35 years of international investment management experience, including corporate restructuring and capital strategy. He currently serves as chief executive of Slovenia-based sporting goods manufacturer Elan.
Datavault AI (NASDAQ:DVLT) will present its potential tort litigation tokenization capabilities at the Mass Torts Made Perfect conference on October 13–15, 2026.
The conference takes place at the Bellagio in Las Vegas. CEO Nathaniel T. Bradley will present at 3:45 p.m. PT, introducing the capabilities to mass tort practitioners and litigation funders. Company executives will be available for meetings throughout the event.
DataMeds AI (MEDS) has implemented cost controls, primarily reducing corporate management positions, to focus workforce spending on commercializing ChemoFx.
The diagnostic test helps oncologists select chemotherapy regimens, initially for gynecologic cancers only. ChemoFx was recently included for the first time in a Humana Medicaid coverage policy for gynecologic cancers. The update follows DataMeds' September 11, 2026 acquisition of Helomics, including its Predictive Oncology division.
Predictive Oncology controls over 70,000 de-identified tumor samples across over 130 tumor types, including approximately 20,000 ovarian cancer samples. DataMeds intends to seek research collaborations using data from the samples and is preparing additional ChemoFx data analyses for peer review. Discussions have begun with healthcare organizations about adding ChemoFx to cancer testing programs where appropriate.